PTHS director granted 103k equity awards at $13.50 鈥� Form 4

Q: What did Matthew Pauls receive according to the PTHS Form 4?

He was granted 25,478 RSUs and 77,640 stock options at a $13.50 exercise price.

Q: When do the Pelthos Therapeutics options granted to Matthew Pauls expire?

The options expire on 07/02/2035 .

Q: How does the RSU and option vesting schedule work for PTHS director Matthew Pauls?

One-third vested on 07/02/2025 ; the remaining two-thirds vest in equal quarterly installments over the next two years.

Q: Did the Form 4 report any stock sales by the PTHS director?

No. The filing only covers acquisitions of derivative securities; no shares were sold.

[Form 4] Channel Therapeutics Corporation Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Pelthos Therapeutics Inc. (PTHS) 鈥� Form 4 filing dated 07/07/2025 details initial equity awards to director Matthew Pauls.

Restricted Stock Units (RSUs): 25,478 units granted on 07/02/2025 at an exercise price of $13.50. One-third vests immediately on the grant date; the remainder vests quarterly over two years.
Stock Options: 77,640 options granted the same day at an identical $13.50 strike price, following the same vesting schedule and expiring 07/02/2035.
Post-grant holdings: Pauls now directly holds 25,478 RSUs and 77,640 options, totaling 103,118 shares underlying derivative securities.
The filing reflects an acquisition (Code 鈥淎鈥�) of derivative securities; no shares were sold.
Governance implication: Equity-based compensation aligns the director鈥檚 incentives with shareholders while introducing limited dilution risk due to the relatively small share count.

Positive

Alignment of interests: Equity awards encourage director focus on share price appreciation.
No share sales: The reporting person only acquired derivative securities, suggesting continued confidence.

Negative

Potential dilution: Up to 103,118 new shares could be issued if awards fully vest and options are exercised.

Insights

TL;DR 鈥� Routine director equity grant; limited dilution, neutral impact.

The Form 4 shows standard incentive alignment: Matthew Pauls received 25,478 RSUs and 77,640 options at $13.50, vesting over two years with an immediate 33% cliff. The structure motivates near-term performance while extending retention to mid-2027. At 103k shares, the grant appears modest for a listed biotech and unlikely to materially affect the share count. No dispositions or 10b5-1 plans were reported. Overall, this is a normal board compensation action rather than a signal about fundamental business changes.

07/07/2025 - 09:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pauls Matthew

(Last)

(First)

(Middle)

C/O PELTHOS THERAPEUTICS INC.

4020 STIRRUP CREEK DRIVE, SUITE 110

(Street)

DURHAM

27703

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Pelthos Therapeutics Inc. [ PTHS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$13.5	07/02/2025		A		25,478		07/02/2026⁽¹⁾	07/02/2035	Common Stock	25,478	⁽¹⁾	25,478	D
Stock Option	$13.5	07/02/2025		A		77,640		07/02/2026⁽²⁾	07/02/2035	Common Stock	77,640	⁽²⁾	77,640	D

Explanation of Responses:

1. On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

2. On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

	/s/ Matthew Pauls	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Matthew Pauls receive according to the PTHS Form 4?

He was granted 25,478 RSUs and 77,640 stock options at a $13.50 exercise price.

When do the Pelthos Therapeutics options granted to Matthew Pauls expire?

The options expire on 07/02/2035.

How does the RSU and option vesting schedule work for PTHS director Matthew Pauls?

One-third vested on 07/02/2025; the remaining two-thirds vest in equal quarterly installments over the next two years.

Did the Form 4 report any stock sales by the PTHS director?

No. The filing only covers acquisitions of derivative securities; no shares were sold.

AG真人官方

[Form 4] Channel Therapeutics Corporation Insider Trading Activity

Insights

FAQ

What did Matthew Pauls receive according to the PTHS Form 4?

When do the Pelthos Therapeutics options granted to Matthew Pauls expire?

How does the RSU and option vesting schedule work for PTHS director Matthew Pauls?

Did the Form 4 report any stock sales by the PTHS director?

NYSE:CHRO

CHRO Rankings

CHRO Latest News

CHRO Latest SEC Filings

CHRO Stock Data

AG真人官方

Trending News

[Form 4] Channel Therapeutics Corporation Insider Trading Activity

Insights

Corporate Governance Expert neutral

FAQ

What did Matthew Pauls receive according to the PTHS Form 4?

When do the Pelthos Therapeutics options granted to Matthew Pauls expire?

How does the RSU and option vesting schedule work for PTHS director Matthew Pauls?

Did the Form 4 report any stock sales by the PTHS director?

NYSE:CHRO

CHRO Rankings

CHRO Latest News

CHRO Latest SEC Filings

CHRO Stock Data